Updates ·
Health notices · Monday 28 September
3 notices from the agencies today, in plain words, each with the original linked.
FDA approves Synjardy (empagliflozin and metformin)
FDA · Approval
If you have type 2 diabetes, the FDA has approved Synjardy, which combines empagliflozin and metformin, as an add-on to diet and exercise to improve blood sugar control.
Synjardy is for adults and for children aged 10 years and older. It also comes as Synjardy XR for adults.
Empagliflozin is not recommended for type 1 diabetes, where it may increase the risk of diabetic ketoacidosis; use is limited to type 2 diabetes because of the metformin component.
FDA approved ZITUVIMET (sitagliptin and metformin)
FDA · Approval
If you have type 2 diabetes, the US Food and Drug Administration has approved ZITUVIMET (sitagliptin plus metformin hydrochloride). It is used as an adjunct to diet and exercise to improve glycemic control (blood sugar levels).
ZITUVIMET is not recommended for people with type 1 diabetes mellitus. It also has not been studied in people with a history of pancreatitis (inflammation of the pancreas).
FDA approval of MOUNJARO (tirzepatide) for type 2 diabetes
FDA · Approval
If you have type 2 diabetes, the US Food and Drug Administration has approved MOUNJARO (tirzepatide). It is used with diet and exercise to improve glycemic control, which means better blood sugar management.
MOUNJARO is for adults and for pediatric patients aged 10 years and older.
MOUNJARO works as a GIP and GLP-1 receptor agonist, which are medicines that act on hormone receptors involved in blood sugar regulation.